Position in ERAS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,633,230
+$7,612,542 QoQ
Shares Held
595,379
+9.6% QoQ
Ownership
0.191%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 75.45798558565217.ToString("F0")%
None 24.542014414347836.ToString("F0")%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026WELLINGTON MANAGEMENT GROUP LLP holds $14,418,547,095 across 180 Biotechnology names. ERAS ranks #72 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,212,589 | $1,434,549,489 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,837,459 | $1,419,694,318 | |
| 3 | ARGX |
Argenx SE
|
1,021,457 | $745,918,971 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,935,925 | $640,539,501 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
6,027,819 | $586,205,394 | |
| 6 | CYTK |
Cytokinetics Inc
|
8,009,489 | $527,905,416 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
6,391,816 | $479,961,458 | |
| 8 | ASND |
Ascendis Pharma A/S
|
1,757,633 | $402,023,391 |
All Filings in ERAS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,633,230 | 595,379 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $2,020,688 | 543,196 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $1,309,262 | 600,580 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,124,776 | 885,651 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $1,164,701 | 850,147 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $1,168,836 | 465,672 | Shares | Defined | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||